| Document |
Document Title |
|
WO/2021/104215A1 |
Provided is the use of decidual NK cells and cell subsets thereof in the preparation of a drug for treating infertility-related diseases. Experiments have confirmed that the decidual NK cells and cell subsets thereof treat endometrial gr...
|
|
WO/2021/097781A1 |
The present invention provides a pyridine methylene piperidine derivative and use thereof. Specifically, the present invention provides a novel pyridine methylene piperidine derivative and a pharmaceutical composition containing the comp...
|
|
WO/2021/092358A1 |
The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing,...
|
|
WO/2021/088739A1 |
A method and a device for determining an intestinal probiotic supplement formula, a storage medium, and a processor. The method comprises dividing intestinal probiotics into a plurality of probiotic groups, and dividing each probiotic gr...
|
|
WO/2021/086948A1 |
Non-hormonal contraception compositions and methods for contraception are provided. One embodiment provides an antibody or an antigen binding fragment thereof that specifically binds to one or more sperm antigens and inhibits the ability...
|
|
WO/2021/081601A1 |
The present disclosure relates to anti-mullerian hormone (AMH) analogues, more particularly AMH analogues which are agonists of the AMH type II receptor (AMHR2). More particularly, the present disclosure relates to AMH analogues having a...
|
|
WO/2021/085769A1 |
The present invention relates to a composition comprising Botulinium toxin or a salt thereof for increasing an endometrial blood flow rate, a composition for improving an implantation potential, and a pharmaceutical composition comprisin...
|
|
WO/2021/079339A1 |
The present invention relates to a stable parenteral dosage form with a ready-to-inject sterile stable aqueous solution of cetrorelix acetate. The invention also relates to an injection device prefilled with the ready-to-inject sterile s...
|
|
WO/2021/080464A1 |
The invention relates to the field of medicine, and more particularly to reproductive medicine, and can be used in treating women who have had multiple failed in vitro fertilization attempts. The present method involves testing the methy...
|
|
WO/2021/079536A1 |
This composition for lysis of Staphylococcus aureus or this composition for prevention or therapy of diseases caused by Staphylococcus aureus contains as active ingredients: at least one bacteriophage selected from the group consisting o...
|
|
WO/2021/079986A1 |
A composition for lysing Staphylococcus aureus or a composition for preventing or treating a disease caused by Staphylococcus aureus, said composition comprising, as active ingredients, at least one bacteriophage selected from the group ...
|
|
WO/2021/079435A1 |
This composition is for lysing Staphylococcus aureus or treating or preventing diseases caused by Staphylococcus aureus, and contains, as active ingredients, at least one bacteriophage selected from the group consisting of the bacterioph...
|
|
WO/2021/079984A1 |
The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b...
|
|
WO/2021/076618A1 |
The invention relates to compositions and methods for treating uterine fibroids in vivo, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage and/or reduce stiffness of uterine fibroi...
|
|
WO/2021/075491A1 |
A transdermal absorption-type patch (10) comprises a support body (1) and an adhesive layer (2) layered on the support body (1). The adhesive layer (2) contains: a solid composite body (2a) in which an active ingredient having a molecula...
|
|
WO/2021/076675A1 |
Embodiments of the disclosure include methods and compositions related to prevention of spontaneous miscarriage in an individual. In certain cases, fibroblasts are provided in an effective amount to an individual in need thereof. Alterna...
|
|
WO/2021/073518A1 |
Provided in the present invention is the use of an inhibitor of a plasmin inhibitory factor for preventing and/or treating pre-eclampsia or eclampsia, or the use thereof in the preparation of a drug for preventing and/or treating pre-ecl...
|
|
WO/2021/068239A1 |
Disclosed are a vaginal slow-release administration system for luteal support, a preparation method therefor and a use thereof. The system is a progesterone reservoir type vaginal ring, comprising a core layer, and a film layer double-la...
|
|
WO/2021/070785A1 |
The discovery has been made that immortalized cells derived from porcine kidney macrophages exhibit a high infection susceptibility for various pig infectious virus strains, which has made it possible to provide, inter alia, a method for...
|
|
WO/2021/069542A1 |
The present invention concerns compounds and their use in contraception. These compounds are derivatives of zafirlukast and have been found to inhibit CatSper in human sperm cells in low concentrations.
|
|
WO/2021/069700A1 |
This disclosure relates to crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-diox
o-1,2,3,4-tetrahydrothieno[2,3- d]pyrimidin-6-yl)phenyl)-N'-methoxyurea. It also relate...
|
|
WO/2021/069711A1 |
This disclosure relates to crystalline forms, in particular to Form II of N-(4-(l-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-
methoxy-3-pyridazinyl)-2,4-dioxo-l,2,3,4-tetrahydrothieno[2,
3- d ]py rim idin-6-yl)phenyl)-N'-methox...
|
|
WO/2021/064132A1 |
The invention relates to compositions useful in the treatment of female subjects suffering from menopause related symptoms. There is a strong-felt need for effective treatment and management of such symptoms, which do not rely on estroge...
|
|
WO/2021/063373A1 |
The present invention relates to a compound represented by formula I and a stereoisomer, tautomer, solvate, polymorph thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, a preparation meth...
|
|
WO/2021/057987A1 |
The present invention relates to the field of disease test kits, and provides an application of a reagent for measuring the content of calprotectin in faeces (faecal calprotectin) in preparation of a teratozoospermia screening kit. Accor...
|
|
WO/2021/060281A1 |
The purpose of the present invention is to provide a novel compound which has a prostaglandin E2 (PGE2) receptor EP2/EP4 dual antagonizing effect and is useful as: a preventive or therapeutic agent for a disease selected from cancer, pai...
|
|
WO/2021/052152A1 |
The present invention relates to the technical field of biomedicine engineering, and provides a composition related to soluble dimer immunoadhesin and a method. The dimeric immunoadhesin comprises a dimerized first and second polypeptide...
|
|
WO/2021/054864A1 |
The group of inventions relates to medicine, specifically to andrology, and may be used in pharmacology to correct disorders of spermatogenesis. Proposed is the use of 9-phenyl-2,3,4,5,6,7,8,9-octahydro-1H-selenoxanthene to correct disor...
|
|
WO/2021/054865A1 |
The group of inventions relates to medicine, specifically to pharmacology, and concerns the treatment of fertility disorders in men. Proposed is the use of 9-phenyl-2,3,4,5,6,7,8,9-octahydro-1H-selenoxanthene as an agent for treating pat...
|
|
WO/2021/054866A1 |
The group of inventions relates to medicine, specifically to sexual pathology, and concerns increasing/restoring sexual desire (libido) and improving sexual function caused by androgen deficiency in males. Proposed is the use of 9-phenyl...
|
|
WO/2021/054863A1 |
The group of inventions relates to medicine, specifically to andrology. Proposed is the use of 9-phenyl-2,3,4,5,6,7,8,9-octahydro-1H-selenoxanthene as a stimulator of testicular tissue reparative regeneration processes. Also proposed is ...
|
|
WO/2021/050800A1 |
Provided herein are methods for identifying patient having treatment resistant cancers, such as HPV- related cancers. Therapeutic methods for treatment of cancers are also provided.
|
|
WO/2021/048688A1 |
The invention is related to medicine, in particular urology, and can be used for creating a product for the treatment of erectile dysfunction. The product contains, as the active ingredient, 5-20 wt % of 9-phenyl-sym-octahydroselenoxanth...
|
|
WO/2021/043726A1 |
The disclosure provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives of formula (I), among other compounds, in the treatment of subjects undergoing embryo transfer t...
|
|
WO/2021/042911A1 |
The present invention relates to the field of medicines, and relates to a compound represented by formula (I) and acting as a MAGL inhibitor and a pharmaceutically acceptable salt thereof, a preparation method therefor, use thereof, and ...
|
|
WO/2021/044302A1 |
The invention relates to the preparation of estetrol of formula (I), derivatives thereof protected at positions 3,15α,16α,17β of general formula (III), and 3-hydroxy derivatives thereof protected at positions 15α,16α,17β of general...
|
|
WO/2021/044357A1 |
Compositions and devices comprising apomorphine or pharmaceutically acceptable salts are described. The compositions may comprise a solution of apomorphine, or a pharmaceutically acceptable salt thereof, and a propellant. The solution ma...
|
|
WO/2021/039951A1 |
The present invention addresses the problem of providing a means for improving the diffusibility and dispersibility of an active ingredient in udders, in the case of preparing a formulation of granulocyte-macrophage colony stimulating fa...
|
|
WO/2021/038460A1 |
The present invention relates to methods of treatment of menstrual cycle induced disorders and symptoms with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising ...
|
|
WO/2021/036294A1 |
A vaginal acid-base buffer gel and a preparation method, the gel consisting of the following components by mass: 1%-39% of an oil phase base, 60%-99% of a water phase base, 0.001%-2% of a pH regulator and 0.05%-5% of a bacteriostat, wher...
|
|
WO/2021/039833A1 |
The present invention addresses the problem of providing a novel means for preventing the inhibition of the proliferation of keratinocytes even when the keratinocytes begin to contact with each other. The present invention can solve th...
|
|
WO/2021/036803A1 |
Disclosed is a protein of the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:2, and an application of a long-acting protein preparation prepared from a modified protein in the preparation of a drug for improving sexual dysfunction...
|
|
WO/2021/031148A1 |
Provided are a crystal form of a gonadotropin releasing hormone antagonist, a preparation method therefor, and use thereof. A crystal form C and a crystal form D have high purity, good illumination stability, high temperature stability, ...
|
|
WO/2021/027741A1 |
Provided are a Lactobacillus johnsonii strain (Ljohn-1) and the use thereof. The strain was deposited in the China Center for Type Culture Collection in June, 2019, with the deposit number CCTCC No. M2019426. The strain, a dominant strai...
|
|
WO/2021/027742A1 |
Provided is a Lactobacillus crispatus Lcris-2, which was preserved in the China Center for Type Culture Collection in June 2019 with the preservation number: CCTCC No. M2019427. The strain belongs to the dominant strain of women's vagina...
|
|
WO/2021/027740A1 |
A multi-lactobacillus composition. The multi-lactobacillus composition is a dominant strain separated and selected from the vagina of a healthy woman in China. The multi-lactobacillus composition comprises at least three of the following...
|
|
WO/2021/027937A1 |
The present invention relates to new solid forms (including crystalline and amorphous solids) of relugolix, a compound applied as gonadotropin-releasing hormone (GnRH) receptor antagonist, and a preparation method therefor. The provided ...
|
|
WO/2021/030655A1 |
This document relates to methods and materials for assessing and/or treating hypertensive disorders of pregnancy (e.g., preeclampsia) and/or one or more comorbidities associated with a hypertensive disorder of pregnancy. For example, met...
|
|
WO/2021/023805A1 |
The present invention relates to a compound for treatment of a disease or disorder involving depression, erectile dysfunction, anxiety, sexual dysfunction and/or ejaculatory disorders; or a combination thereof.
|
|
WO/2021/025103A1 |
Provided is a composition capable of effectively exhibiting an effect on a change in hormonal balance. A composition is prepared which is for inhibiting reduction of testosterone and/or dihydrotestosterone and contains a cordyceps milita...
|
